Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA study of more than 192 million records found tirzepatide and semaglutide carried the same risk of depression, anxiety, and suicidal thoughts, and semaglutide came out lower than the earlier GLP-1 drugs.
A meta-analysis of 11 in-vitro studies found GLP-1 drugs raised cellular energy output and cut oxidative exhaust in human cells with no body attached, then graded the evidence very low.
A prespecified SUMMIT secondary analysis split 731 obesity-related HFpEF patients by sex. Women arrived sicker and men more remodeled, but tirzepatide cut worsening-HF-or-death risk about a third in both (HR 0.66 vs 0.61, interaction P 0.81). The one sex difference: in women, symptom relief tracked weight loss.
A new analysis of the FDA's adverse-event database, published July 9 in Obstetrics & Gynecology, looked at menstrual complaints filed for female patients aged 12 to 55 on GLP-1 drugs. Semaglutide flagged for five kinds of disruption (heavy bleeding, spotting between periods, clots, infrequent periods, skipped ovulation), tirzepatide for two, and liraglutide for none. Three drugs on the same receptor, three different menstrual fingerprints, from a spontaneous-report system that can flag a signal but cannot prove cause.
In 15,447 adults from the NIH All of Us program, published in July in Alcohol, Clinical and Experimental Research, current GLP-1 users scored 5 to 11 percent lower on a standard alcohol screen than people about to start the drug. The whole effect came from drinking on fewer days. Drinks per occasion and binge drinking did not budge, a frequency-not-intensity split that reframes the hope that these drugs curb alcohol use disorder.
A real-world study of about 330,000 matched patients published July 8 in Digestive Diseases and Sciences puts hard numbers on the GLP-1 gut toll: 31.9 percent had a gastrointestinal adverse event within a year, gastroparesis was 57 percent more likely, and drug-induced pancreatitis nearly tripled. But the same data cut both ways, with fewer bowel obstructions, null gallbladder findings, and fewer emergency-room visits and hospital admissions overall.
A meta-analysis of nine trials found the dual GLP-1 and glucagon agonist mazdutide cut weight by 6.6 to 11.1 percent across rising doses in obesity, and beat dulaglutide on weight and blood sugar in diabetes. The reviewers rated the obesity numbers very low certainty and the diabetes numbers moderate.
A study across 13 South Korean hospitals found adults who started semaglutide or liraglutide to lose weight were diagnosed with depression, anxiety, and other problems more often than matched non-users, with semaglutide carrying about 3.4 times the depression rate. The comparator was people not on the drug, so detection bias could be doing much of the work.
A retrospective study of 21,250 US patients found adults with chronic pancreatitis on GLP-1 drugs were 41 percent less likely to start long-term opioids, and had fewer nerve blocks, endoscopic procedures, and pancreatic surgeries. It is an association from hospital records, not proof the drugs ease the disease.
A network meta-analysis of 17 trials and 1,230 adolescents ranked semaglutide best for weight, dulaglutide for blood sugar, and others for glucose and blood pressure. But most comparisons were indirect and single-trial, so the leaderboard is a hypothesis, not a head-to-head result.
In 371 adults, semaglutide cut blood eosinophils, a driver of asthma inflammation, by about a third. The drop was bigger in leaner patients and independent of weight lost, pointing at a direct effect on type 2 inflammation.
A review of seven studies and 924 adults found GLP-1 drugs did not raise objectively measured physical activity. Structured exercise held steady; incidental daily movement dipped, by about 1,144 steps in one trial.
A 75,000-patient TriNetX cohort tied GLP-1 use to a 41 percent lower rate of atrial fibrillation in chronic kidney disease. The reduction held in people who were neither diabetic nor obese, where the usual metabolic explanation runs out.
A TriNetX study of GLP-1 receptor agonists found autoimmune thyroiditis went opposite directions by diabetes type: down in type 1 (hazard ratio 0.41), up in type 2 (1.23), with the type 2 signal holding against SGLT2 inhibitors. Thyroid cancer showed no change in any group.
A meta-analysis of 186,598 pregnancies found no significant rise in gestational diabetes, preterm birth, preeclampsia, or hypertension among women exposed to GLP-1 receptor agonists around conception.